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Abstract 
Growing concern that most published results, including those widely agreed upon, may 
be false are rarely examined against rapidly expanding research production. Replications 
have only occurred on small scales due to prohibitive expense and limited professional 
incentive. We introduce a novel, high-throughput replication strategy aligning 51,292 
published claims about drug-gene interactions with high-throughput experiments 
performed through the NIH LINCS L1000 program. We show (1) that unique claims 
replicate 19% more frequently than at random, while those widely agreed upon replicate 
45% more frequently, manifesting collective correction mechanisms in science; but (2) 
centralized scientific communities perpetuate claims that are less likely to replicate even 
if widely agreed upon, demonstrating how centralized, overlapping collaborations 
weaken collective understanding. Decentralized research communities involve more 
independent teams and use more diverse methodologies, generating the most robust, 
replicable results. Our findings highlight the importance of science policies that foster 
decentralized collaboration to promote robust scientific advance. 
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Introduction 
Concern over reliability (1) and reproducibility (2, 3) in science calls into question the 
cumulative process of building on prior results published by others. In a publication 
environment that rewards novel findings over verifications (4, 5), scientists remain 
uncertain about the published claims they assemble into new research designs and 
discoveries. In this paper, we demonstrate a claim replication strategy that repurposes 
high-throughput experiments to evaluate the replication likelihood for tens of thousands 
of scientific claims curated from a wide range of research articles. 
Our strategy builds on the synergy of two advances. First, databases of empirical 
claims on many topics, ranging from material science to biomedicine (6, 7), are extracted 
from literature and linked to digital archives of scientific articles such as MEDLINE and 
Web of Science, making possible systematic analysis of features that characterize the 
provenance of a scientific claim, such as where, when, who, and how many experiments 
provided findings for and against it (8). Second, high-throughput experiments driven by 
consistent, programmable robots have become increasingly widespread, initially in 
genome sequencing (9) but extending to many domains, including drug-gene interactions. 
These experiments provide large-scale biomedical data enabling simultaneous estimation 
of the replication likelihood for many prior published claims.  
Replication failures are typically attributed to systemic bias in a publication 
system that favors positive results (1). This incentivizes questionable research choices 
such as p-hacking (10, 11), “flexible” data analysis (12), low statistical power (13), 
selective reporting (“the file drawer problem”) (14), and confirmation bias (15), which 
generate false results unlikely to replicate in future experiments (12). 
Here we investigate the social and methodological structure of scientific and 
methodological communities that coalesce around scientific claims. What network 
dependencies linking scientists and their experimental methods produce the most robust, 
replicable claims? We hypothesize that an empirical claim tested by a decentralized 
community of non-overlapping teams with diverse training and prior knowledge, using 
distinct methods under varying experimental conditions will produce robust knowledge, 
likely to replicate in future experiments. By contrast, increased collaboration (16), 
growing teams (17), star scientists (18, 19), and expensive, shared equipment trace a 
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pathway to “big science” (20) approaches to knowledge production (Fig. S1), which at 
the extreme involve integrated collaboration of an entire community around massive, 
singular research efforts like the Human Genome Project and the Laser Interferometer 
Gravitational-Wave Observatory (LIGO) (20-22). We hypothesize that a claim tested by 
a centralized or densely connected community involving repeated collaborations and a 
narrow range of methods, knowledge, and conditions is fragile and less likely to replicate 
than those produced by many decentralized or independent labs, while acknowledging 
that some claims can only be explored through massive, integrated collaboration. 
Prior studies simulated the effect of network structure on scientific outcomes, 
suggesting that independent labs should more likely arrive at truth than a connected 
network of scientists, which can more easily propagate early, false results (23-25). A 
more recent experiment demonstrates that decentralized network ties, rather than 
independence, most likely improves the wisdom of crowds (26). Scientific findings could 
also be more or less robust as a function of diverse methods (27, 28) used to corroborate 
them or distinct theories used to motivate them. Consider Jean Perrin’s use of multiple 
experimental techniques and theories to precisely determine Avogadro’s number (29).  
We represent the provenance of a scientific claim with a multilayer network (30, 
31), where each network node depicts a research article reporting a finding about that 
claim. Articles are linked based on whether they (1) agree and the degree to which they 
share (2) scientific collaborators, (3) empirical methodologies, and (4) references to prior 
work (see Fig. 2A). This network representation allows us to analyse the replication 
likelihood for each claim as a function of the epistemic, social, technical and intellectual 
dependencies that underlie it. 
 
High-throughput Claim Replication Strategy 
We examined a corpus of 51,292 scientific claims about chemical/drug-gene/mRNA 
interactions in human systems. We compiled the corpus by using claims about directed 
drug-gene interactions curated from biomedical publications in the most comprehensive 
database, the Comparative Toxicogenomics Database (CTD) (6), recording over one 
million published claims regarding drug-gene interactions. Each scientific claim is a 
triple of drug, gene, and interaction effect. For comparability with high-throughput 
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experiments, we selected interaction effects in which a drug “increases expression” or 
“decreases expression” of an mRNA in humans (effect magnitudes were not recorded). 
The database identifies source articles in which the finding is claimed (i.e., PubMed ID), 
which enabled examination of article content (e.g., methods) and metadata features (e.g., 
authors).  
To estimate replication likelihood, we map our corpus of drug-gene claims to 
high-throughput experimental data from the NIH LINCS L1000 program. The program 
generated 1.3M gene expression profiles from 42,080 chemical and genetic perturbagens 
across cell lines, time points, and doses (32). We used profiles induced by chemical 
perturbagens, amounting to 19,811 small molecule compounds (including FDA approved 
drugs). To measure relative gene expression resulting from chemical perturbations, the 
LINCS L1000 team computed robust z-scores that represent differential expression 
signatures. We combined the z-scores across signatures using a bootstrapped 
modification of Stouffer’s method (33, 34) to generate drug-gene interaction triples of (i) 
drug, (ii) gene (mRNA), and (iii) combined z-score indicating experimental effect size 
and effect direction. We matched drug-gene interaction triples from the LINCS L1000 
experiments to triples in CTD, and found 51,292 drug-gene interaction claims at the 
intersection, corresponding to 60,159 supportive and 4,253 opposing findings from the 
literature, annotated from 3,363 scientific papers. 
We distinguish between robustness to social, methodological and intellectual 
dependencies and robustness to experimental conditions (27) like time, dosages, cells, or 
tissues, which delimit the potential for a drug-gene interaction to generalize. In all 
subsequent models, we control for the variability of drug-gene interactions in LINCS 
L1000 to disentangle features of experimental and biological heterogeneity from global 
patterns of (in)dependence. 
Our high-throughput replication strategy evaluates reliability of the overall 
scientific claim rather than of any particular finding. The latter would require precise 
reproduction of the original research following the original experimental protocol (35). 
Nevertheless, collective agreement across many articles may serve as evidence of a 
generalized claim robust to any one technique (28, 36), scientist, research group, or 
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biological setting (e.g., cell line), thereby justifying increased confidence in the claim’s 
widespread scientific and biomedical relevance. 
 
Results 
We observe a long-tailed distribution of published findings in support of a given 
scientific claim (Fig. 1A). Most claims are supported by findings in one (89%) or two 
(8%) articles, while few appear in many articles. The distribution of experimental effect 
sizes over drug-gene interactions in LINCS L1000 decays much more slowly (Fig. 1D). 
Published findings widely agree on the direction of drug-gene interactions (93%) 
(Fig. 1A). In contrast, the majority of interaction effect-sizes (59%) in LINCS L1000 
across experimental conditions are statistically undetermined (Fig. 1D). We find that 
consensus in the literature is positively associated with social dependencies. A pair of 
findings about a drug-gene interaction reported in papers with shared author(s) are 
significantly more likely to agree in the direction of the effect (0.989; 95% CI: 0.984, 
0.993; 2,514  pairs of papers) than findings reported in socially independent papers 
(0.889; 95% CI: 0.884, 0.893; 20,846 pairs of papers) (Fig. S2). 
We also find that generalizable interactions, which converge across experimental 
conditions in LINCS L1000, are more likely to replicate published claims (RR = 0.60) 
than interactions that vary across conditions (RR = 0.52), which are indistinguishable 
from random (RR = 0.501) in our corpus (Fig. 1E). We define the replication success (R 
= 1; 0 otherwise) of a claim as the effect size (combined z-score) in LINCS L1000 
matching the direction (increase or decrease) of the effect claimed in literature (see SM). 
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Fig. 1. Aligning drug-gene claims from the literature with interactions from high-
throughput experiments to evaluate replication likelihood. (A) On top, the 
distribution of drug-gene claims against the number of supporting and opposing findings 
in the literature on a log-log scale. On bottom, the proportion of supporting and opposing 
findings on aggregate. (B) Posterior distributions of support in the biomedical literature 
for a sample of drug-gene claims. For each claim, we summarize the probability of 
support (dashed line) using the lower bound on the 95% posterior credible intervals 
(PCI). (C) Typology of drug-gene claims from the literature on the basis of claim’s 
distribution of support compared to the null value of 0.5. Number of claims included in a 
category provided in brackets. (D) Effect sizes (combined z-scores) for drug-gene 
interactions derived from LINCS L1000 experiments. On top, the distribution of drug-
gene interactions against absolute experimental effect size in LINCS L1000 (log-log 
scale). On bottom, the proportion of significant and insignificant interactions in LINCS 
L1000. We established significance at the 0.05 level by bootstrapping (10,000 iterations) 
the combined z-score for each of the 51,292 interactions sampling from experiments 
across different cell lines, durations, and dosages. (E) Observed, 𝑅𝑅!"#, versus expected, 𝑅𝑅!"#$, replication rate (see SM) for drug-gene claims differentiated by significance in 
LINCS L1000 and support from literature. (F) Relative replication increase for each type 
of claim, indicating the percentage increase of 𝑅𝑅!"#  relative to random 𝑅𝑅!"#$  or 
100 × RRobs!RRrand
RRrand
. (G), Variability (coefficient of variation) in LINCS L1000 across cell 
lines, durations, and dosages for each type of claim. We established statistical 
significance using a nonparametric bootstrap test with 100,000 iterations. Error bars 
represent SEM. 
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A central concern is whether the replication problem applies only to novel and 
rare claims or if it also afflicts widely supported results, as recently hypothesised (37, 
38). To integrate collective support in the literature over multiple claim sources, we 
design a binomial Bayesian model with a uniform prior that accommodates skewed 
distributions (39) like that of findings per claim we observed. To estimate the probability 
of support for each drug-gene claim, we assume that the number of supportive published 
findings 𝛾  in 𝑛  findings about that claim is drawn from a binomial distribution, 𝑝(γ θ  ~ Bin γ n, θ  (see SM). The model allocates higher probability to scientific claims 
unanimously supported in a large number of articles and lower probability to infrequent 
and disputed claims (Fig. 1B). 
 We find a strong relationship between scientific support in the literature 𝐿!"#$ 
and the probability of replication success, ranging from 0.507 (95% CI: 0. 492, 0.522) for 
claims with the least support to 0.705 (95% CI: 0.665, 0.743) for claims with the largest, 
controlling for biological and experimental variability in LINCS L1000 (Fig. S3A). 
When we consider only significant drug-gene interactions (Fig. S3B), which generalize 
across experimental conditions, the probability of replication for top-supported claims 
reaches 0.798 (95% CI: 0. 751, 0.845).  
 To examine the hypothesis that convergent drug-gene claims more likely replicate 
than those claimed rarely or disputed in literature, we categorized claims on the basis of 
their distribution of support (Figs. 1C and S4; see SM). We found that claims with “Very 
high” (RRI = 45.4%; SEM ± 13.5%) and “High” (RRI = 34.5%; SEM ± 7.6%) support in 
the biomedical literature are significantly more likely to replicate in high-throughput 
experiments than claims with “Low” (RRI = 19%; SEM ± 1.1%) and “Moderate” (RRI = 
16.2%; SEM = 3.3%) support (Fig. 1F). The replication of “Low” and “Moderate” 
support claims is consistent with estimates (~11–25%) from recent biomedical 
reproducibility studies (2, 3), but those receiving support from multiple sources is much 
higher. “Contradictory” claims are significantly less likely to replicate than random. They 
are also associated with greater experimental variability (Fig. 1G), indicating that 
collective disagreements among findings truthfully signal unstable drug-gene interactions 
with low replication likelihood. These results suggest that findings reported in a single 
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scientific article may be fallible, but viewed as a system of converging and diverging 
findings, science exhibits collective correction. 
Independent and decentralized sources of evidence should increase claim 
robustness. Figure 2A presents a schematic of a multilayer network 𝑀 = (𝑉! ,𝐸! , 𝐿) for 
a claim. In each network layer L, nodes 𝑉 are scientific papers and edges 𝐸 between pairs 
of papers represent either a binary relationship of agreement (𝐿!) or the amount of 
overlap measured with the Jaccard coefficient, between the two papers’ sets of authors 
(𝐿!), methodologies (𝐿!), and references to prior literature (𝐿!). Our independence scores 
for social, methodological, and prior knowledge range between 0 (dependent) and 1 
(independent), and can be viewed as the probability that any two randomly chosen 
findings about a claim are obtained by disconnected sets of authors, methods, and 
references, respectively (see SM). Figure 2B-C present schematics of bipartite networks 
of authors connected to the papers they publish. To quantify the centralization of research 
communities C, we compute the Gini coefficient of the authors’ degree distribution (see 
Fig. 2D-E). 
We examine the impact of network dependencies on claim replicability by fitting 
logistic regression models that predict replication success against the measures described 
above and defined for each claim, using a sub-corpus of 2,493 claims with determined 
direction of the drug-gene effect in the literature (𝐿!"#$ = 68%  PCI > µ < 68%  PCI) and 
in LINCS L1000. Figure 2F shows that the odds ratios (OR) of replication increase 
substantially with the increase of scientific support in the literature 𝐿!"#$ (OR 23.20; 95% 
CI: 9.08, 59.3), social independence 𝑆!"# (OR 6.31; 95% CI: 4.07, 9.79), methodological 
independence 𝑀!"# (OR 6.30; 95% CI: 3.44, 11.53), and prior knowledge independence 𝐾!"# (OR 5.53; 95% CI: 2.58, 11.84). By contrast, claim replication decreases with 
centralization 𝐶  (OR 0.36; 95% CI: 0.27, 0.48). Our estimates indicate that claim 
robustness, defined here as multiple decentralized evidence, increases replication success 
(Fig. 2G-M). When all predictors are modelled simultaneously (Fig. 2F), however, 
centralization and support in the literature account for the rest, suggesting that centralized 
academic training and extensive collaboration mediates the application of research 
techniques and attention to prior research. 
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Fig. 2. Multilayer networks of social, methodological, and prior knowledge 
dependences predict replication likelihood. (A) Examples of multilayer claim 
networks. Each layer 𝐿 represents a co-paper network: nodes are scientific papers; pairs 
of papers are connected by an unweighted edge if they agree on the effect direction (𝐿!), 
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and a weighted edge proportional to the overlap (Jaccard coefficient or JC) between the 
two papers’ authors  (𝐿!), methodologies  (𝐿!), and references to prior literature (𝐿!). 
Dashed red line in the agreement layer indicates opposing edges. For clarity, we only plot 
edges above the mean JC value for overlapping methods. (B-C) Example of centralized 
and decentralized bipartite networks. Edges connect authors (rectangles) to papers they 
published (circles). Centralization C is the Gini coefficient of the authors’ degree 
distribution. (D-E) Lorenz curves showing different level of centralization, corresponding 
to the examples in B and C. (F) Logistic regression models with replication success as the 
response variable and predictors modelled (top) independently and (bottom) 
simultaneously. Predictors are rescaled !!!!"#  (!)!"# ! !!"#  (!) for comparability. (G-M) Predicted 
probabilities (PP) of claim replication PP 𝑅 = 1 = !"#  (!!!!!!)!!!"#  (!!!!!!) for logistic models of 
independent predictors with 95% error bounds.  
 
An alternative explanation of replication success is the biological tendency for 
some drug-gene interactions to generalize across conditions and so replicate in future 
experiments. Figure 2F shows that experimental variability has a small, insignificant 
negative effect, and that support from multiple, decentralized teams are much more 
informative predictors of replication success. 
Our combined model also controls for journal prominence J, which we measure 
with journal eigenfactor (40), a score that credits journals receiving many citations from 
highly cited journals. Claim replication increases with journal prominence (Figs. 2F and 
2L), but prominent journals are responsible for only a tiny fraction of all claims, which 
warrants our evaluation strategy and the practice of extracting and archiving findings 
from a wide range of journals (6). 
Figure 3 shows that by accounting for scientific support, centralization, and social 
independence, we can identify claims with high replication probability. Claims supported 
by many publications have about 45 percent higher probability to replicate when 
investigated by decentralized versus centralized communities (Figs. 3A and S8). Even if a 
claim garners wide support, if studied exclusively by a centralized scientific community, 
the claim is indistinguishable in replication probability from a claim reported in a single 
paper. This suggests a condition under which collective correction in science is 
undermined, when one or several scientists exercise disproportionate influence on team 
assembly and research across multiple investigations of a claim. Claims robust to 
multiple, socially independent investigations have a 55 percent higher probability to 
	   11	  
replicate than those studied by small clusters of overlapping collaborators (Figs. 3B and 
S9). These effects all account for the experimental and biological variability of drug-gene 
interactions. 
 
 
 
Fig. 3. Contour plots of the probability of claim replication based on network 
dependencies and support in the literature. (A) The probability of claim replication is 
greater in decentralized communities of scientists, after controlling for variability in 
LINCS L1000 across cell lines, durations, and dosages. (B) The probability of claim 
replication increases with support in the literature and social independence, after 
controlling again for experimental variability. 
 
Discussion 
Extensive (22) and often overlapping scientific collaboration (16), along with cumulative 
advantage processes that create central, star scientists (19), produce centralized “big 
science” communities with dense methodological and intellectual dependencies. Such 
communities tend to publish fragile findings. Our research points to the importance of 
science policies that foster competition and decentralized collaboration to promote robust 
and replicable scientific advance. Our analysis demonstrates the utility of large-scale 
experiments coupled with enriched article content and metadata to diagnose the 
replicability of published research. Our findings suggest a calculus for evaluating the 
system-level trade-off between investments in robust, replicable knowledge, which 
comes at the price of larger, but weaker, preliminary insight. 
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Materials and Methods 
 
DATA 
 
High-throughput drug-gene interactions 
We used the Library of Integrated Network-based Cellular Signatures (LINCS) Phase I 
L1000 data set to estimate claim replication (32). The data set measures the expression of 
978 landmark genes treated with wide range of perturbagens across cell lines, time 
points, and doses (concentration), resulting in approximately 1.3M profiles. The 
experimental profiles are aggregated to 473,647 signatures, as represented in Level 5 data 
we used to perform our analysis. The landmark genes are subsequently used to infer gene 
expressions for the remaining genes in the human genome. In addition to the 978 
landmark genes, we consider 9,196 for which the LINCS L1000 project estimated to be 
well inferred, resulting in 10,174 Best INferred Genes (BING) in total. With respect to 
perturbagen types, we used the set of small-molecule compounds (19,811 compounds), 
which includes a subset of approximately 1,300 FDA-approved drugs. We accessed the 
data file GSE70138_Broad_LINCS_Level5_COMPZ_n118050x12328_2017-03-
06.gctx.gz and metadata from the GEO depository at 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE70138. 
 
Published drug-gene interactions 
We analysed curated data about published interactions between chemicals/drugs and 
genes/mRNAs released by the Comparative Toxicogenomics Database (CTD) (6) on June 
7 2016. (The current CTD data release is available here: http://ctdbase.org/downloads/.) 
To align triples of drug, gene, and interaction effect in CTD to corresponding triples in 
the experimental signatures from LINCS L1000, we performed the following procedures. 
First, we selected drug-gene interactions about Homo sapiens, comprising approximately 
40% of the CTD data. Second, CTD reports the form of the gene (e.g., mRNA, protein) 
that is implicated, and we selected only mRNA as LINCS L1000 measures gene 
expression at the mRNA level. Third, we mapped chemical names and Entrez gene IDs in 
the CTD to perturbagen names and Entrez gene IDs in LINCS L1000. Fourth, to ensure 
comparability to the LINCS L1000 signatures, we selected drug-gene interactions with a 
single interaction effect, either “decreases expression” or “increases expression”, defining 
the direction of the effect that chemical/drug manifests on a gene/mRNA. Note that we 
do not consider complex interactions with multiple, nested effects in our analysis. 
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Likewise, interactions for which the direction of the effect is not specified, such as 
“affects binding”, are not considered. The resulting corpus at the intersection of LINCS 
L1000 and CTD comprises 51,292 drug-gene claim combinations of 605 unique drugs 
and 9,123 unique genes, annotated from 3,363 scientific articles.  
 
METHODS 
 
Combining LINCS L1000 effect sizes 
The LINCS L1000 team applied a moderated Z-scoring procedure to estimate weighted 
average signatures. For each drug-gene interaction, we computed a combined gene 
signature using Stouffer’s method (33, 34) Z = Zi
k
i=1! , where 𝑍! is an experimental z-score 
and 𝑘 is the number of signatures. Using this procedure, we aggregated experiments 
about drug-gene interactions across cell lines, dosages, and durations into a combined 
effect size (z-score). Some drug-gene interactions generalize across conditions, whereas 
others are context specific. We define as generalized drug-gene effect sizes that are 
significant at the 0.05 level. To measure significance, for each drug-gene interaction, we 
performed 10,000 bootstrap iterations on the combined z-score, sampling from 
experiments performed under different cell lines, dosages, and durations. Conventionally, 
if the 95% confidence intervals do not contain the null value of 0, we consider a drug-
gene interaction as generalized. 
 
Measuring variability in LINCS L1000 
To measure how each drug-gene interaction varies across cell lines, dosages, and 
durations in LINCS L1000, we computed the coefficient of variation. The coefficient of 
variation (CI) is the ratio of the standard deviation to the absolute value of the mean: 𝐶𝐼 = !!"#(!). In comparison to scale-dependent measures of variability, CI is a normalized 
measure that allows us to make comparisons across drug-gene interactions. 
 
Modelling claims’ support in literature  
We apply a binomial Bayesian model (39, 41, 42) to estimate the probability of scientific 
support 𝜃 for each drug-gene claim given the number of supportive findings 𝛾 in all 
findings N reported in CTD about a particular drug-gene interaction. We assume that the 
prior distribution of 𝜃 is uniform on the interval [0,1]: θ!~Uniform(min = 0,max = 1). 
This uninformative prior considers all possible probability support values 𝜃 as equally 
possible and is suitable for the skewed distribution of findings over drug-gene claims. We 
assume that the number of findings in support of a drug-gene claim 𝛾 follows a binomial 
distribution 𝑝(𝛾 𝑁,𝜃   ~  Binomial 𝛾 𝑁,𝜃  where Binomial 𝛾 𝑁,𝜃   ~    𝑁𝛾 𝜃!(1−𝜃)!!! . Then, the posterior density for 𝜃 is 𝑝 𝜃 𝛾 ∝   𝜃! 1− 𝜃 !!! . We approximated 
the posterior density of 𝜃 for each drug-gene claim by performing 10,000 Markov chain 
Monte Carlo (MCMC) sampling iterations (2,500 burn in iterations) for each drug-gene 
claim using the Metropolis–Hastings MCMC sampler implemented in the PyMC package 
(version 2.3.6) for Python. To improve convergence, we approximate the maximum 
posterior (MAP) before running the MCMC sampler (39). 
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Typology of drug-gene claims 
To avoid setting arbitrary thresholds to categorize claims by their support in literature, we 
used the posterior distributions from our Bayesian model of support. For each claim, we 
estimated the overlap between the posterior credible intervals (PCI) and the null value of 
µ = 0.5 (Fig. 1C): Very high support claims (𝐿!"#$ 95% PCI exceeds µ) yield agreement 
from multiple papers (~7 papers on average), amounting to 325 claims that are supported 
by 2,241 findings, but only opposed by 21; High support claims 
(80% PCI ≥ 𝐿!"#$ < 95% PCI exceeds µ) yield agreement from 3 papers on average (N = 
1,083 claims, supported and opposed in 3,525 and 42 articles, respectively); Moderate 
support claims (68% PCI ≥ 𝐿!"#$ < 80% PCI exceeds µ) yield agreement from 2 papers 
on average (N = 3,743 claims, supported and opposed in 7,557 and 38 articles, 
respectively); Low support claims  (68% PCI ≥ 𝐿!"#$ < 80% PCI contains µ) are 
overwhelmingly supported by a single paper or opposed by virtually the same number of 
papers that support them such that the direction of the effect is undetermined (N = 46,064 
claims, supported and opposed in 46,735 and 3,668 articles, respectively). Contradictory 
claims (𝐿!"#$  68% PCI is smaller than µ) generate lower support than expected as a 
greater number of papers reported findings in the opposite direction (N = 77 claims, 
supported and opposed in 101 and 484 articles, respectively) (Fig. S4). 
 
Null model for estimating relative replication increase 
We define replication as a binary variable 𝑅 ∈ {0,1}, where R = 1 indicates that the 
direction (increase or decrease) of the effect claimed in literature is matched by the 
combined z-score in LINCS L1000, and R = 0 otherwise. To estimate the amount of 
relative replication increase (RRI), we first empirically established the expected or 
random replication rate 𝑅𝑅!"#$ by iteratively randomizing LINCS L1000 drug-gene 
interactions. For each randomization, we computed the replication rate for all significant 
drug-gene claims (N = 21,181) as well as for the collection of very high support (N = 
136), high support (N = 406), moderate (N = 1,908), low (N = 18,688), and contradictory 
(N = 43) claims against the drug-gene interactions from LINCS L1000 that randomly 
matched them. We repeated the estimation procedure 100,000 times to generate 
randomized distributions, mean randomized replication rates RRrand, and standard errors 
of the RRrand (or SEM) for each claim type. This randomization model takes into account 
biases in the distribution of published claims, as when disproportionately more claims of 
a certain direction, either  “increasing” or “decreasing”, are present. This allows us to 
conservatively estimate the expected replication rate on the basis of empirical data, rather 
than assuming a random null value of 0.5. We bootstrapped (100,000 iterations with 
replacement) the observed replication vector for each type of claim to generate 
distributions of observed replication rates, mean observed replication rates RRobs, and the 
standard error of RRobs (or SEM). We used the randomized and bootstrapped distributions 
for each type of claim to estimate the percentage relative replication increase: 𝑅𝑅𝐼 =  100 × RRobs!RRrand
RRrand
.    
 
Claim multilayer networks 
To investigate the robustness of drug-gene claims, we represent each claim as a 
multilayer network 𝑀 = 𝑉! ,𝐸! , 𝐿  (30). The network consists of four layers, which we 
plot using the Multilayer Networks Library for Python (Pymnet) (43). Nodes 𝑉! in the 
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network are scientific papers. In each layer L, edges 𝐸 between pairs of papers represent 
either a binary relationship of agreement and disagreement about effect direction (𝐿!), or 
the amount of overlap between the two articles’ authors (𝐿!), methods (𝐿!), and 
references (𝐿!). For this analysis, we exclude claims with low support as estimated via 
our Bayesian model because they are primarily reported by a single paper and therefore, 
lack independence and robustness. To examine the impact of claim robustness on the 
probability of replication in high-throughput experiments, we interrogated only 
interactions that produce a replication signal by posting a statistically significant effect 
size. These are claims that generalize across experimental and biological conditions in 
LINCS L1000. By exploring only statements having significant agreement within the 
literature and within LINCS L1000, we can directly examine the effect of social, 
methodological, and epistemic dependencies on shaping agreement between literature 
and high-throughput experiment. The sub-corpus of claims both supported in the 
literature and significant within LINCS L1000 consists of 2,493 claims, associated with 
6,272 supporting and 339 opposing findings from 1,282 papers. For each claim, we create 
a multilayer co-paper network and model the predictive power of each layer on the 
replicability of a claim in the LINCS L1000 experiments. 
 
Quantifying overlap between articles’ authors, methods, and references  
To quantify the amount of overlap between papers, we used the Jaccard coefficient (JC). 
For any two sets of paper’s attributes—i.e., authors, methods, or references—𝐴! and 𝐴!, 
JC is the size of intersection divided by the size of the union: 𝐽𝐶 𝐴! ,𝐴! = |!!  ∩  !!|!!   !   !!   !  |!!  ∩  !!|. The resulting quantity represents the edge weight 
between a pair of articles in the respective network layers of shared authors (𝐿!), 
methods (𝐿!), and references (𝐿!). Each drug-gene claim constitutes an undirected, 
multilayer network of papers connected via such weighted edges across layers (see Fig 
2A).  
 
Independence of findings 
We define an independence score IND as the proportion of maximum possible edges (44) 
in a network layer 𝐸!"# = !!(!!!)/! not present, 𝐼𝑁𝐷 = !!"#!  !!!"# , where 𝑊 is the sum over 
all weighted edges in a claim’s respective layer of shared authors, methods, or references. 
The independence scores for social, methodological, and prior knowledge approaches 1 
when most papers with findings in support of a claim share no common authors, methods, 
and references, and 0 when all papers share all of their authors, methods, and references, 
respectively. 
 
Social independence 
We used the MEDLINE/PubMed database to extract the set of authors for each paper. To 
measure the overlap between two sets of authors, we need individual identifiers for 
authors. Authors’ name disambiguation is a common problem in research on scientific 
knowledge production. We used the individual identifiers based on author last name and 
initials. We note that because we assessed authors separately for each claim, our 
conservative matching procedure is very unlikely to produce false positive author 
linkages, and so our author co-paper network should be considered a lower bound for 
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author co-paper density. For the sub-corpus of 2,493 claims, sourced from 1,282 papers, 
we estimated a mean of 6.4 authors per paper and a mean of 23.5 authors per scientific 
community defined here as the total number of authors that have published papers 
reporting a drug-gene claim. For the set of papers supporting a claim, we applied JC to 
measure the overlap between any two sets of papers’ authors and utilized the output to 
compute claim’s social independence 𝑆!"# using our independence score. 
 
Methodological independence 
We compiled a controlled vocabulary of 3,074 terms (incl. synonyms) concerning 
methods, techniques, and experimental apparatus used in biomedical research using 
ontologies of biomedical investigations (45) and statistics (46). We then used the 
RESTful API Web Service of Europe PMC to query the methods sections from 4.4 
million full text articles and extracted, on aggregate, 13,095 terms for 488 articles (38%). 
In parallel, for all 1,282 articles that share a drug-gene claim, we applied fuzzy matching 
against our vocabulary using the difflib module in Python and extracted 12,135 terms 
from abstracts available in MEDLINE/PubMed. We combined the outputs from the two 
search procedures. Then, for the set of papers supporting a claim, we again used JC to 
measure the overlap between any two sets of papers’ methods and then employed our 
independence score to measure claim’s methodological independence 𝑀!"#. 
 
Prior knowledge independence 
To examine whether a pair of publications is exposed to similar or dissimilar prior 
information, we use the notion of bibliographic coupling (47), i.e., the number of 
citations any two papers share. To compute bibliographic coupling, we used the Web of 
Science citation data. Out of 1,282 papers sharing a drug-gene claim with at least one 
other paper, we mapped 1,234 PubMed IDs to Web of Science IDs and performed 
bibliographic coupling on this subset using Python modules Tethne (48) and NetworkX 
(49). 880 of our 1,234 papers were coupled bibliographically by at least one paper. 
Consistent with the procedure we applied to measure shared authors and methods, we 
used JC to measure the overlap between any two sets of papers’ citations and then 
employed our independence score to measure claim’s prior knowledge independence 𝐾!"#.    
 
Centralization of scientific communities 
To quantify the centralization of scientific communities in the bipartite author-article 
networks for each claim, we employed the Gini coefficient. The Gini coefficient is used 
to measure the heterogeneity of distributions in social and information networks (50). 
The coefficient ranges between 0 and 1. In the context of a bipartite author-article 
network, the coefficient approaches 0 when all investigators author equal numbers of 
articles about a claim and increases to 0.3 and above (depending on the number of 
articles), when one investigator authors all articles and all others author only one. The 
Gini coefficient can be also represented as a percentage ranging from 0 to 100, as in 
Figure 2D-E. While other measures of network centralization are available (e.g., 
Freeman’s centralization (51)), the Gini coefficient, and the Lorenz curve on which it is 
based, is independent from the underlying degree distribution, making it suitable for 
comparisons among networks with different size and mean degree (50, 52). 
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Journal prominence 
To measure journal prominence, we employed the journal eigenfactor score (40). The 
eigenfactor score acts like a recursively weighted degree index by rating journals highly 
that receive citations from journals that are themselves highly cited. Using the Web of 
Science database, we computed journal eigenfactor scores for 3,162 papers (94% of all 
3,363 papers in our corpus) published in 656 journals between 1995 and 2016. For the 
sub-corpus of 1,282 papers with shared drug-gene claims, we recovered 1,212 papers or 
95% published in 496 journals. For each claim, we computed mean journal eigenfactor 
scores by averaging over the eigenfactor score of all journals that published a paper 
reporting findings in support of the claim. The distribution of mean journal eigenfactor 
scores (i.e., journal prominence) per claim is highly skewed (Figs. S4 and S5), indicating 
that claims receive overwhelmingly support from findings published in low and medium 
ranked journals. This highlights the value of archiving findings across a wide range of 
journals, as do CTD and other scientific database projects, which makes possible our 
large-scale evaluation of scientific output. 
 
Shared authors and scientific agreement 
To examine whether papers with shared authors are more likely to agree on the direction 
(“increasing expression” or “decreasing expression”) of the drug-gene interaction, we 
identified all pairs of papers with shared or distinct authors that reported findings about 
the same drug-gene pair irrespective of the directionality of the effect. We found that 
among the 2,514 edges between papers with shared authors, 2,486 (98.9%) agreed on the 
direction of the effect. By comparison, among the 20,846 pairs of papers with distinct 
authors, 18,527 (88.9%) agreed on the direction of the effect. To examine the differences 
in agreement rates among papers with common versus distinct authors, we performed a 
two-tailed bootstrap test (100,000 samples) (Fig. S2). 
 
Predictors of replication success 
We estimate logistic regression models to predict claim replication R [Replicated = 1, 
Non-replicated = 0] as a function of support in the literature 𝐿!"#$, social independence 𝑆!"#, methodological independence 𝑀!"#, prior knowledge independence 𝐾!"#, 
centralization 𝐶, journal prominence 𝐽, and experimental variability 𝑉. First, for 
exploratory purposes, we model each variable independently (see Table S1): 
     logit  P 𝑅 = 1 = 𝛽! + 𝛽!×  𝐿!"#$     𝛽! + 𝛽!×  𝑆!"#     𝛽! + 𝛽!×  𝑀!"#     𝛽! + 𝛽!×  𝐾!"#     𝛽! + 𝛽!×  𝐶     𝛽! + 𝛽!×    𝐽     𝛽! + 𝛽!×  𝑉. 
 
Second, we model our variables simultaneously (see Table S2):  
 logit  Ρ 𝑅 = 1 = 𝛽! + 𝛽!×𝐿!"#$ + 𝛽!×𝑆!"# + 𝛽!×𝑀!"# + 𝛽!×𝐾!"# + 𝛽!×𝐶 + 𝛽!×𝐽 + 𝛽!×𝑉. 
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Third, we estimate two interaction models to examine the effect of support in the 
literature on replication success as a function of social independence and centralization, 
respectively (see Figs. 3 and S8–9):  
 logit  P 𝑅 = 1 = 𝛽! + 𝛽!×𝐿!"#$×  𝑆!"# + 𝛽!×𝑉 𝛽! + 𝛽!×𝐿!"#$×  𝐶 + 𝛽!×𝑉. 
 
To estimate and visualized the logistic regression models, we used the “glm” function 
and the “effects” (53) and “sjPlot” (54) packages for R. 
 
 
Data Analysis  
 
Robustness analysis  
Some of our variables are correlated (e.g., methodological independence and prior 
knowledge independence; see Fig. S7), which is to be expected as they capture related 
dimensions of scientific knowledge production. We performed a multicollinearity test 
using the variance inflation factor (VIF). The variance inflation factors vary from low for 
variability in LINCS L1000 (VIF = 1.015), journal prominence (VIF = 1.135), and 
support in literature (VIF = 1.534) to moderate for centralization (VIF = 3.162), 
methodological independence (VIF = 3.752), prior knowledge independence (VIF = 
4.681), and social independence (VIF = 4.900). We observe no predictor with high 
variance inflation factor, i.e., VIF ≥ 10. We removed the two variables with the highest 
VIF > 4 and refit our logistic regression model. In the refitted model, both support in the 
literature and decentralization of scientific communities remain strong and significant 
predictors of replication success (Fig. S10). Further, we verified that the effects of 
support from the literature and community centralization on claim replication success are 
not dominated by outliers. Recall the long-tailed distribution of findings per claim, with 
few claims receiving support from many published findings (Fig. 1A). We removed 
claims supported by 10 or more findings, amounting to 26 claims supported by 426 
findings and found that support from the literature (OR 34.785; 95% CI: 12.518, 96.662, 
P = 1.00e-11) and community centralization (OR 0.335; 95% CI: 0.249, 0.451, P = 
5.57e-13) remain strong and significant predictors of replication success, after controlling 
for biological and experimental variability in LINCS L1000 (OR 0.726; 95% CI: 0.429, 
1.232; P = 0.236). Similarly, the distribution of findings per paper and per pair of papers 
is heterogeneous (Fig. S11). We removed the largest set of 796 drug-gene claims reported 
by a pair of papers and still found that the effect of support from the literature (OR 
19.512; 95% CI: 7.193, 52.929, P = 5.37e-09) and centralization (OR 0.432; 95% CI: 
0.287, 0.65, P = 5.71e-05) holds and is not explained by variability in LINCS L1000 (OR 
0.574; 95% CI: 0.279, 1.181; P = 0.131). 
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Fig. S1. A continuum of “small” to “big” science communities defined as the total 
number of authors that have published papers reporting a drug-gene claim. (A-B) 
Distribution of scientific communities of different sizes against the number of 
communities for the corpus of 51,292 and for the sub-corpus of 2,493 claims, 
respectively.  
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Fig. S2. Publications that share authors are more likely to agree about the direction 
of a drug-gene interaction than publications with distinct authors, computed among 
pairs of papers reporting claims in the sub-­‐corpus	  of	  2,493 claims. (A) Bootstrap 
samples of agreement (1 = agreement, 0 = disagreement) among pairs of papers that 
reported findings about the same drug-gene interaction depending on whether the pairs of 
papers shared (2,514 pairs of papers) or did not share author(s) in common (20,846 pairs 
of papers). (B) A two-tailed bootstrap test of difference between means indicates that 
papers with one or more authors in common have significantly higher agreement rates 
than pairs of papers with distinct authors (100,000 samples with replacement). The solid 
dark line indicates the sample mean, the dashed line indicates 95% CI, and the red line 
indicates the null hypothesis. 
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Fig. S3. Replication success increases with claim’s probability of support in the 
literature. (A) Probability of claim replication estimated via a logistic regression model 
with replication as the response variable and support in the literature and experimental 
variability as predictors, for the whole corpus of 51,292 claims. (B) Same as A but for the 
subset of 21,181 significant drug-gene interactions in LINCS L1000. For each variable, 
we indicate odds ratios (OR), 95% confidence interval, and significance.   
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Fig. S4. Description of claim types in the whole	  corpus	  of	  51,292	  claims. (A) Mean 
number of findings supporting or opposing the direction of the effect for a scientific 
claim across our typology. (B) Cumulative distribution of the probability of support in the 
literature, including a schematic of our claim typology.  
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Fig. S5. Estimates of probability density functions for variables of interest in our 
corpus using a normal kernel function. We used the normal kernel function to estimate 
probability density functions.   
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Fig. S6. Estimates of probability density functions for our variables for the sub-
corpus of claims with determined direction of the drug-gene effect in CTD and 
LINCS L1000. As in Fig. S5, we used the normal kernel function to estimate probability 
density functions. 
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Fig. S7. Pearson correlation coefficients between network indices. Social, 
methodological, and prior knowledge (in)dependencies are positively correlated with 
each other and negatively correlated with the network centralization of scientific 
communities. N = 2,493 claims.    
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Fig. S8. Claims reported by centralized communities less likely replicate. (A-C), 
Logistic interaction model with claim replication as the response variable regressed on 
support in the literature and centralization as interacting predictors, controlling for 
variability in LINCS L1000 across cell lines, durations, and dosages. Predictors are 
rescaled !!!!"#  (!)!"# ! !!"#  (!) for comparability. N = 2,493 claims. *** P < 0.001; **  P < 0.01; 
*  P < 0.05. 
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Fig. S9. Claims reported by multiple socially independent teams more likely 
replicate. (A-C) Logistic interaction model with claim replication as the response 
variable regressed on support from the literature and social independence as interacting 
predictors, controlling for variability in LINCS L1000 across cell lines, durations, and 
dosages. Predictors are rescaled !!!!"#  (!)!"# ! !!"#  (!) for comparability. N = 2,493 claims. 
*** P < 0.001; **  P < 0.01; *  P < 0.05. 
 
 
 
 
 
 
 
Variability in LINCS L1000
Pr
ob
ab
ilit
y 
of
 c
la
im
 re
pl
ica
tio
n
0.0
0.2
0.4
0.6
0.8
1.0
0.0 0.2 0.4 0.6 0.8 1.0
A B
C
 B SE Exp(B) 95% CI 
     
Intercept –0.59*** 0.148 0.553 [0.414, 0.738] 
Support in literature*Social 
independence 
3.36*** 0.384 28.786 [13.56, 61.1] 
Variability in LINCS L1000 –0.351 0.268 0.704 [0.417, 1.189] 
Social independence
Pr
ob
ab
ilit
y 
of
 c
la
im
 re
pl
ica
tio
n
0.0
0.2
0.4
0.6
0.8
1.0
0.0 0.2 0.4 0.6 0.8 1.0
Support in literature
0
0.2
0.5
0.8
1
	   31	  
 
 
Fig. S10. Support in the literature and decentralization of scientific communities 
remain strong and significant predictors of claim replication success after we 
account for multicollinearity. Logistic model with replication as the response variable, 
including only predictors with relatively low variance inflation factor (VIF < 4). 
Predictors are rescaled !!!!"#  (!)!"# ! !!"#  (!) for comparability. N = 2,491 claims. *** P < 0.001; 
**  P < 0.01; *  P < 0.05. 
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Fig. S11. Papers and pairs of papers are differentiated by the number of findings 
they report (in the sub-corpus of 2,493 claims). (A) Distribution of papers against the 
number of supporting findings they report. (B) Distribution of pairs of papers against the 
number of supporting findings they report. 
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Variable B SE Exp(B) 95% CI 
     
Intercept –0.762*** 0.195 0.47 [0.318, 0.684] 
Support in literature 3.144*** 0.479 23.2 [9.078, 59.287] 
 
Intercept 
 
0.414*** 
 
0.046 
 
1.513 
 
[1.384, 1.654] 
Journal prominence 2.379*** 0.564 10.795 [3.571, 32.638]  
 
Intercept 
 
–1.053*** 
 
0.193 
 
0.349 
 
[0.239, 0.509] 
Social independence 1.843*** 0.224 6.312 [4.069, 9.793] 
 
Intercept 
 
–1.004*** 
 
0.255 
 
0.366 
 
[0.222, 0.604] 
Methodological independence 1.841*** 0.308 6.301 [3.444, 11.527] 
 
Intercept 
 
–1.14** 
 
0.376 
 
0.32 
 
[0.153, 0.668] 
Prior knowledge independence 1.71*** 0.388 5.53 [2.584, 11.835] 
 
Intercept 
 
0.585*** 
 
0.065 
 
1.794 
 
[1.579, 2.039] 
Variability in LINCS L1000 -0.444 0.264 0.641 [0.382, 1.077] 
 
Intercept 
 
0.8*** 
 
0.062 
 
2.224 
 
[1.972, 2.51] 
Centralization –1.018*** 0.149 0.361 [0.27, 0.484] 
 
Table S1. Logistic regression models with claim replication R [Replicated = 1, Non-
replicated = 0] as response variable and predictors modelled independently. 
Predictors are rescaled !!!!"#  (!)!"# ! !!"#  (!) for comparability. N = 2,493 claims (N = 2,491 in 
the Journal eigenfactor model); *** P < 0.001; **  P < 0.01; *  P < 0.05. 
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Variable B SE Exp(B) 95% CI 
     
Intercept –0.693* 0.352 0.5 [0.251, 0.996] 
Support in literature 2.729*** 0.595 15.316 [4.772, 49.153] 
Journal prominence 1.019 0.563 2.769 [0.918, 8.355]  
Social independence 0.632 0.486 1.881 [0.725, 4.877] 
Methodological independence –0.183 0.585 0.833 [0.265, 2.621] 
Prior knowledge independence –0.029 0.769 0.971 [0.215, 4.383] 
Variability in LINCS L1000 –0.41 0.271 0.664 [0.391, 1.128] 
Centralization –0.734** 0.268 0.48 [0.284, 0.812] 
 
Table S2. Logistic regression models with claim replication R [Replicated = 1, Non-
replicated = 0] as response variable and predictors modelled simultaneously. 
Predictors are rescaled !!!!"#  (!)!"# ! !!"#  (!) for comparability. N = 2,491 claims; *** P < 0.001; 
**  P < 0.01; *  P < 0.05. 
 	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
